Alexa 40 ml Inj
Enoxaparin is a low molecular weight heparin with a high anti-Xa activity and with a low anti-lla or anti- thrombin activity. At doses required for the various indications, Enoxaparin does not increase bleeding time. At preventive doses, Enoxaparin causes no notable modification of activated Partial Thromboplastin Time (aPTT). It neither influences platelet aggregation nor binding of fibrinogen to platelets. Enoxaparin is primarily metabolized in the liver.
Enoxaparin is indicated for:
Treatment of deep vein thrombosis, with or without pulmonary embolism.
Treatment of unstable angina and non-Q-wave myocardial infarction, administered concurrently with
Prevention of thrombus formation in the extra-corporal circulation during haemodialysis.
Prophylaxis of venous thromboembolic disease (prevention of blood clot formation in the veins), in
particular those which may be associated with orthopedic or general surgery.
Prophylaxis of venous thromboembolic disease in medical patients bedridden due to acute illness, including cardiac insufficiency, respiratory failure, severe infections, rheumatic diseases.
Alexa 40: Each pre-filled syringe (0.4ml) contains 4000 anti-Xa IU equivalent to 40 mg Enoxaparin Sodium USP.
Alexa 60: Each pre-filled syringe (0.6ml) contains 6000 anti-Xa IU equivalent to 60 mg Enoxaparin Sodium USP.
Alexa 80: Each pre-filled syringe (0.8ml) contains 8000 anti-Xa IU equivalent to 80 mg Enoxaparin Sodium USP.